Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600135037) titled 'A prospective, single-arm, phase II study of neoadjuvant retlirafusp alfa injection plus SOX in patients with TGFBR2-wild-type locally advanced gastric or gastroesophageal junction adenocarcinoma' on Oct. 23.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Xijing Hospital, Air Force Medical University
Condition:
Resectable locally advanced gastric or gastroesophageal junction adenocarcinoma, clinical stage T3-4aN+M0, HER2-negative and TGFBR2 wild-type
Intervention:
Neoadjuvant retlirafusp alfa plus SOX group:All participants receive neoadjuvant retlirafusp alfa combined with SOX: ...